SCHEMBL6386124

SCHEMBL6386124

CNC(=O)NC.O=C(O)c1cc(Cl)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.54
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
KMO O15229 4/20 0.49
KDM4E B2RXH2 3/20 0.49
KDM6B O15054 1/20 0.49
TET3 O43151 1/20 0.49
KDM4A O75164 1/20 0.49
BBOX1 O75936 1/20 0.49
KDM5A P29375 1/20 0.49
KDM5C P41229 1/20 0.49
ASPH Q12797 1/20 0.49
KDM4D Q6B0I6 1/20 0.49
TET2 Q6N021 1/20 0.49
ALKBH5 Q6P6C2 1/20 0.49
KDM7A Q6ZMT4 1/20 0.49
KDM8 Q8N371 1/20 0.49
TET1 Q8NFU7 1/20 0.49
EGLN2 Q96KS0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202448 0.88 ALDH1A1 (0.61) KDM4CALDH1A1MAPTL3MBTL1KMO
SCHEMBL31151693 0.88 ALDH1A1 (0.61) KDM4CALDH1A1MAPTL3MBTL1KMO
SCHEMBL29026601 0.86 ALDH1A1 (0.59) KDM4CALDH1A1MAPTL3MBTL1KMO
Hydrochloric Acid SCHEMBL27576045 0.86 ALDH1A1 (0.59) KDM4CALDH1A1MAPTL3MBTL1KMO
SCHEMBL9440140 0.86 ALDH1A1 (0.59) KDM4CALDH1A1MAPTL3MBTL1KMO
Hydrochloric Acid SCHEMBL1682029 0.86 ALDH1A1 (0.59) KDM4CALDH1A1MAPTL3MBTL1KMO
SCHEMBL177518 0.81 KDM4C (0.62) KDM4CALDH1A1MAPTL3MBTL1NPC1
SCHEMBL30155195 0.81 KDM4C (0.62) KDM4CALDH1A1MAPTL3MBTL1NPC1
Hydrochloric Acid SCHEMBL700397 0.79 KDM4C (0.60) KDM4CALDH1A1MAPTL3MBTL1NPC1
SCHEMBL899382 0.74 MAPT (0.59) KDM4CALDH1A1MAPTL3MBTL1KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076488-B2 Antiproliferative agents; angiogenesis inhibitors; anticancer agents BAYER HEALTHCARE LLC (US) 2011-12-13 US disclosed
EP-1608639-A2 NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS Bayer Pharmaceuticals Corporation (US) 2005-12-28 EP disclosed
US-20050038031-A1 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders BAYER HEALTHCARE LLC 2005-02-17 US disclosed
WO-2004078748-A2 NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038031-A1 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders CCNC, UACA, SLC14A1 KDM4C 926/4885ALDH1A1 1861/4885MAPT 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.